Corcept Therapeutics (CORT) Q4 2025 earnings review
Record Demand Masked by Operational Hiccups and Expense Bloat
Corcept Therapeutics finds itself in a paradoxical quarter. On the surface, underlying demand is booming, with management citing record new prescriptions for hypercortisolism. However, actual Q4 revenue decelerated sequentially, dropping to $202.1 million from $207.6 million in Q3. The culprit? Operational disruptions during a much-needed specialty pharmacy transition. Furthermore, the cost of preparing for a massive 2026 pipeline expansion is crushing current profitability. Net income dropped 21% YoY in Q4 as SG&A expenses surged 56%. Despite these execution stumbles, management issued aggressive FY26 revenue guidance of $900M–$1B, signaling confidence that the pharmacy bottlenecks are finally resolved and volume growth will overwhelm the cost structure.
🐂 Bull Case
The CATALYST study continues to drive physician awareness, proving that hypercortisolism is far more prevalent in difficult-to-treat diabetes than previously thought. This expands the core market dramatically.
The ROSELLA trial's success in platinum-resistant ovarian cancer (PROC) validates cortisol modulation in oncology. With a PDUFA date of July 2026, this opens an entirely new, multi-hundred-million-dollar revenue vertical.
🐻 Bear Case
SG&A expenses jumped 56% to $130.2M in Q4, crushing the operating margin down to 2.2% from 13.9% a year ago. If revenue growth stalls, this bloated cost structure will destroy earnings.
This is the second time in 2025 the company has blamed a 'specialty pharmacy vendor' for failing to fulfill surging demand. Operational bottlenecks are leaving millions in potential revenue on the table.
⚖️ Verdict: ⚪
Neutral. The underlying clinical data and demand narrative are incredibly strong, but repeated unforced operational errors (pharmacy constraints) and a reversing profitability trend require investors to take 2026 execution entirely on faith.
Key Themes
Pharmacy Transition Bottlenecks Restrict Growth
Sales growth is decelerating due to fulfillment, not demand. Q4 revenue fell sequentially from $207.6M to $202.1M. Management cited 'operational disruptions' while transitioning to a new specialty pharmacy vendor. While they claim the transition is now complete and February 2026 is on track for record new patient starts, this operational bottleneck has plagued the company for multiple quarters and represents a significant execution risk.
SG&A Explosion Crushing Margins
A reversing trend in profitability is a major red flag. Operating margin collapsed to 2.2% in Q4 from 13.9% a year ago. This was driven by a massive 56% YoY spike in SG&A expenses (to $130.2M), likely tied to commercial preparations for the relacorilant launch. While investing in a launch is necessary, the sheer scale of the spend is driving net income down (-21% YoY) even as annual revenue climbs.
Relacorilant Cushing's Launch Impending
Management is heavily reliant on the approval of relacorilant to succeed Korlym. Positioned as a vastly superior drug with no drug-induced hypokalemia, the company is engaging with the FDA to finalize the approval path. If approved, this drug is expected to become the new standard of care and drive the bulk of the company's aggressive 2026 revenue guidance.
Oncology Platform Validated (ROSELLA)
The successful Phase 3 ROSELLA study is a massive win, proving cortisol modulation works in solid tumors. With a 35% reduction in the risk of death in platinum-resistant ovarian cancer, an NDA is under review with a PDUFA date of July 11, 2026. This transitions Corcept from a niche endocrinology company into a broader oncology player.
Aggressive Share Repurchases Continue
Despite margin compression, Corcept returned significant capital to shareholders, spending $245.9 million in 2025 on stock repurchases and net employee stock settlements. This signals management's absolute confidence that the current profitability dip is temporary and shares are undervalued relative to the pipeline's potential.
Other KPIs
Decelerating. Down from $141.2 million in FY24, an almost 30% drop. This highlights the cost of commercial expansion and pipeline development, requiring top-line growth to accelerate just to keep earnings flat.
Stable. Down slightly from $603.2 million at the end of 2024, reflecting the aggressive $245.9 million spent on share repurchases. The balance sheet remains bulletproof with zero debt mentioned, providing ample runway for the upcoming commercial launches.
Guidance
Accelerating. The midpoint of $950 million implies a ~25% YoY growth rate compared to FY25's $761.4 million. This is a significant acceleration from the 13% growth achieved in 2025. It suggests management believes the pharmacy capacity issues are entirely behind them and that expanded sales force efforts will fully capitalize on the CATALYST study demand.
Key Questions
Pharmacy Transition Finality
You stated the transition to the new specialty pharmacy is 'fully complete'. What specific volume capacity does the new vendor have, and what leading indicators confirm they will not be overwhelmed by the guided 25% growth in 2026?
SG&A Expense Trajectory
Q4 SG&A jumped 56% year-over-year. Is $130 million the new quarterly baseline run-rate as we head into the relacorilant launches, or were there one-time transition costs embedded in the Q4 number?
Teva Litigation Update
With the Teva generic Korlym patent litigation appeal hanging over the company, what is the latest update from the Federal Circuit Court of Appeals, and what contingency plans are in place if the ruling is unfavorable before relacorilant's approval?
Relacorilant Cushing's NDA Status
You mentioned engaging with the FDA to 'determine the best path forward' for the relacorilant NDA following a Complete Response Letter. Can you clarify the specific deficiencies cited in the CRL and the timeline for resubmission?